Cai Xiong, Zhou Hua, Wong Yuen Fan, Xie Ying, Liu Zhong Qiu, Jiang Zhi Hong, Bian Zhao Xiang, Xu Hong Xi, Liu Liang
Research and Development Division, School of Chinese Medicine, Hong Kong Baptist University, Kowloon Tong, Kowloon, Hong Kong, China.
J Ethnopharmacol. 2007 Mar 1;110(1):39-48. doi: 10.1016/j.jep.2006.09.008. Epub 2006 Sep 16.
QFGJS is an herbal preparation, and its pronounced effectiveness in treating adjuvant-induced arthritis (AIA) has been previously demonstrated. We herein aimed to confirm its anti-arthritic effect on collagen-induced arthritis (CIA) in rats. CIA was established in female Wistar rats with intradermal injection of type II bovine collagen at the base of the tail of animals. CIA rats were treated daily with oral administration of different doses of QFGJS beginning on the day of the induction of arthritis (day 0, the prophylactic treatment) or on the day after the onset of arthritis (day 13, the therapeutic treatment) until day 30. The results showed that prophylactic treatment with QFGJS significantly suppressed the onset of arthritis, and therapeutic treatment with QFGJS markedly reduced paw swelling and ESR levels even in the established CIA. Radiologic and histopathologic changes in the arthritic joints were also significantly reduced in the QFGJS-treated versus vehicle-treated rats. Moreover, the serum levels of pro-inflammatory cytokines TNF-alpha, IL-1beta, and IL-6 were markedly lowered in the QFGJS-treated rats. Hence, our studies demonstrate the quality, safety, and effectiveness of QFGJS as an anti-arthritic agent, which makes QFGJS a strong candidate for further clinical trials on rheumatoid arthritis (RA) patients.
祛风蠲痹胶囊(QFGJS)是一种草药制剂,其在治疗佐剂性关节炎(AIA)方面的显著疗效此前已得到证实。我们在此旨在确认其对大鼠胶原诱导性关节炎(CIA)的抗关节炎作用。通过在雌性Wistar大鼠尾部基部皮内注射II型牛胶原蛋白建立CIA模型。从关节炎诱导当天(第0天,预防性治疗)或关节炎发作后一天(第13天,治疗性治疗)开始,每天对CIA大鼠口服给予不同剂量的QFGJS,直至第30天。结果表明,QFGJS预防性治疗可显著抑制关节炎的发作,即使在已建立的CIA模型中,QFGJS治疗性治疗也能显著减轻爪肿胀和血沉水平。与赋形剂处理的大鼠相比,QFGJS处理的大鼠关节的放射学和组织病理学变化也显著减少。此外,QFGJS处理的大鼠血清中促炎细胞因子TNF-α、IL-1β和IL-6的水平明显降低。因此,我们的研究证明了QFGJS作为一种抗关节炎药物的质量、安全性和有效性,这使得QFGJS成为对类风湿性关节炎(RA)患者进行进一步临床试验的有力候选药物。